Marshall Wace’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Marshall Wace’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-160,390	Closed	-$345K	–	3100
2024 Q3	$345K	Hold	160,390	–	–	﹤0.01%	2075
2024 Q2	$828K	Buy	160,390 +806	+0.5%	+$4.24K	﹤0.01%	1774
2024 Q1	$854K	Buy	159,584 +134,766	+543%	+$932K	﹤0.01%	1719
2023 Q4	$193K	Buy	+24,818	New	+$85K	﹤0.01%	1984
2023 Q2	–	Sell	-30,551	Closed	-$81.6K	–	3063
2023 Q1	$81.6K	Buy	+30,551	New	+$118K	﹤0.01%	2514
2022 Q2	–	Sell	-8,189	Closed	-$97K	–	3944
2022 Q1	$97K	Buy	+8,189	New	+$146K	﹤0.01%	3199
2021 Q4	–	Sell	-18,345	Closed	-$820K	–	4361
2021 Q3	$820K	Sell	18,345 -11,296	-38%	-$551K	﹤0.01%	2131
2021 Q2	$1.61M	Buy	+29,641	New	+$1.75M	0.01%	1557
2021 Q1	–	Sell	-4,642	Closed	-$504K	–	2936
2020 Q4	$504K	Buy	+4,642	New	+$424K	﹤0.01%	1455
2020 Q3	–	Sell	-2,446	Closed	-$261K	–	1992
2020 Q2	$261K	Buy	+2,446	New	+$220K	﹤0.01%	1361
2018 Q2	–	Sell	-1,310	Closed	-$170K	–	869
2018 Q1	$170K	Buy	+1,310	New	+$143K	0.01%	527

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Marshall Wace's SYRS Position: Q4 2024 in Review

Marshall Wace sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2024, closing a stake of 160,390 shares — an estimated $345K sold.

Marshall Wace first reported a position in SYRS in Q1 2018 and held it in 11 quarters. The position peaked at $1.61M in Q2 2021. 44 funds tracked by Wall St. Rank hold SYRS as of Q4 2024.

Marshall Wace reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Marshall Wace sold 160,390 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $345K.
Marshall Wace first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 11 quarters.
Marshall Wace's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1.61M in Q2 2021.
44 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Marshall Wace's 13F filing for Q4 2024, filed 13 Feb 2025.